The FTC is not anti-direct selling. It’s pro-truth in advertising.
The DSA misses the mark.
Bubak et al v. GOLO, LLC
21-cv-492, E.D. Cal.
(March 2021)
GOLO’s Release Supplement
Implying that the supplement mitigates and prevents diabetes, heart disease, and Alzheimer’s disease by claiming that it is “the Natural Solution to Insulin Resistance”
Misleadingly marketing the supplement as “Clinically Proven” when the company relies on pilot studies that it paid for and that have not been peer reviewed or published in legitimate scientific publications
Pending
The DSA misses the mark.
TINA.org reader takes issue with this product’s deceptive packaging.
Don’t let this company blindside you with its deceptive pricing.
Lawsuit pokes holes in company’s Swiss branding.
Why are these airport vendors slyly charging consumers for “employee benefits”?